CNS Pharmaceuticals, Inc.
CNSP
$4.59
-$0.30-6.14%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -5.58% | -6.68% | 23.37% | 3.22% | 10.59% |
| Total Depreciation and Amortization | 27.03% | 14.71% | 14.71% | 14.29% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -89.92% | -86.74% | -84.87% | 25.12% | 40.68% |
| Change in Net Operating Assets | 139.81% | 149.96% | -353.96% | -249.05% | -170.60% |
| Cash from Operations | 11.33% | 19.30% | -14.47% | -93.92% | -37.22% |
| Capital Expenditure | -480.95% | -333.33% | -90.91% | -7.69% | -7.69% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -480.95% | -333.33% | -90.91% | -7.69% | -7.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.27% | 1.10% | 12.46% | 19.77% | 26.01% |
| Issuance of Common Stock | -80.90% | -39.95% | -10.99% | 261.59% | 227.32% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -108.05% | 1,322.16% | 435.19% | 478.70% | 501.77% |
| Cash from Financing | -82.50% | -36.74% | -5.53% | 295.14% | 257.83% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -182.54% | -87.49% | -52.32% | 481.62% | 384.79% |